Nhs_choices Bthft Bradford Teaching HospitalsNHS Foundation Trust NHS Choices
  • Text Size

  • Language

    loading

08 - Malignant Disease

NICE Technologies Applicable to this BNF Section
TA Number TA Subject Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs, procurement of devices or changes to care pathways? (Yes/No/TA Not Applicable to this organisation)
TA299 Leukaemia (chronic myeloid)(TA299) Yes
TA296 Lung cancer (non small-cell, anaplastic lymphoma kinase fusioon gene, previoulsy treated) - crizotinib (TA296) Yes
TA295 Breast cancer (HER2 negaticve, oeatrogen receptor positive, locally adbanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295) Yes
TA289 Myelofibrosis (spenomegaly, symptoms) - Ruxulitinib (TA289) Yes
TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285) Yes
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284) Yes
TA273 Hyperplasia (benign prostatic)  - tadalafil (terminbated appraisal) (TA273) Yes
TA272 Urothelial tract carcinoma (transitional cell, advanced, metaststic) - vinflunine (TA272) Yes
TA270 Leukaemia (acute myeloid) - decitabine (terminated appraisal) (TA270) Yes
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269) TA not applicable to this organisation (Systemic treatments for this indication are managed by Leeds Teaching Hospitals NHS Foundation Trust)
TA268 Melanoma (stage III or IV) - ipilimumab (TA268) TA not applicable to this organisation (Systemic ttreatments for this indication are managed by Leeds Teaching Hospitals NHS Foundation Trust)
TA265 Bone metastases from solid tumours - denosumab (TA265) Implementation in progress
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263) Yes
TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy) (TA259) Yes
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (first-line) (TA258) Yes
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257) Yes
TA255 Prostate cancer - cabazitaxel (TA255) Yes
TA254 Multiple Sclerosis (relapsing -remitting) - fingolimod (TA254) TA not applicable to this organisation (Multiple sclerosis patients are managed by Leeds Teaching Hospitals NHS Foundation Trust - however, any pateints who have commenced therapy will continue to receive their therapy if they are admitted to this organisation)
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard dose imatinib (TA251) Yes
TA250 Breast cancer (advanced) - eribulin (TA250) Yes
TA243 Follicular lymphoma - rituximab (review) (TA243) Yes
TA242 Colorectal cancer (metastatic) - second line - cetuximab, bevacizumab and panitumumab (review) (TA242) Yes
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib imatinib (intolerant, resistant) (TA214) Yes
TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240) Yes
TA239 Breast cancer (metastatic) - fulvestrant (TA239) Yes
TA235 Osteosarcoma - mifamurtide (TA235) TA not applicable to this organisation (treatment of osteosarcoma is undertaken at Leeds Teaching Hopsitals NHS Foundation Trust)
TA228 Multiple myeloma (first-line) - bortezomib and thalidomide (TA228) Yes
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapay) (TA227) Yes
TA226 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226) Yes
TA222 Ovarian cancer (relapsed) - trabectedin (TA222) Yes
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219) TA not applicable to this organisation (Renal cancers are all managed by Leeds Teaching Hospitals NHS Foundation Trust
TA218 Myelodysplastic syndromes - azacitidine (TA218) Yes
TA216 Leukaemia (lymphocytic) - bendamustine (TA216) Yes
TA215 Renal cell carcinoma (first-line metastatic) - pazopanib (TA215) TA not applicable to this organisation (Renal cancers are all managed by Leeds Teaching Hospitals NHS Foundation Trust)
TA214 Breast cancer - bevacizumab (in combination with a taxane) (TA214) Yes
TA212 Colorectal cancer (metastatic) - bevacizumab (TA212) Yes
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) Yes (any patient who is identified as being suitable for this treatment is referred to Leeds Teaching Hospitals NHS Foundation Trust)
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208) Yes
TA207 Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207) Yes
TA206 Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206) Yes
TA202 Chronic lymphocytic leukaemia - ofatumumab (TA202) Yes
TA200 Hepatitis C - peginterferon alfa and ribavirin (TA200) Yes
TA196 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196) TA not applicable to this organisation (patients with these cancer types are referred to Leeds Teaching Hospitals NHS Foundation Trust)
TA193 Leukaemia (chronic lymphocytic, replased) - rituximab (TA193) Yes
TA192 Lung cancer (non-small-cell, first-line) - gefitinib (TA192) Yes
TA191 Gastric cancer (advanced) - capecitabine (TA191)  Yes
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance) - (TA190) Yes
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189) TA not applicable to this trust (patients with these cancers are referred to Leeds Teaching Hospitals NHS Foundation Trust)
TA185 Soft tissue sarcoma - trabectedin (TA185) TA not applicable to this trust (due to the rarity of this type of cancer, all patients are referred to Leeds Teaching Hospitals NHS Foundation Trust)
TA184 Lung cancer (small-cell) - topetecan (TA184) Yes
TA183 Cervical cancer (recurrent) - topetecan (TA183) Yes
TA181 Lung cancer (non-small-cell, first-line treatment) - pemetrexed (TA181) Yes
TA179 Gastrointestinal stromal tumours sunitinib (TA179) Yes
TA178 Renal cell carcinoma (TA178) Yes (suitable pateints are referred to the renal cancer team at Leeds Teaching Hospitals NHS Foundation Trust)
TA176 Colorectal cancer (first-line) - cetuximab (TA176) Yes
TA175 Lung cancer (non-small-cell, second line) - gefitinib (terminated apprasial) (TA175) Yes
TA174 Leukaemia (chronic lymphocytic, first-line) - rituximab (TA174) Yes
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172) TA not applicable to this organisation (head and neck cancers all managed by Leeds Teaching Hospitals NHS Foundation Trust)
TA171 Multiple myeloma - lenalidomide (TA171) Yes
TA169 Renal cell carcinoma - sunitinib (TA169)  Yes (all renal cancers are referred to the renal cancer team at Leeds Teaching Hospitals NHS Foundation Trust)
TA162 Lung cancer (non-small-cell) - erlotinib (TA162) Yes
TA149 Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149) TA not applicable to this organisation (head and neck cancers all managed by Leeds Teaching Hospitals NHS Foundation Trust)
TA148 Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148) Yes
TA145 Head and neck cancer - cetuximab (TA145) TA not applicable to this organisation (head and neck cancers all managed by Leeds Teaching Hospitals NHS Foundation Trust)
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab (TA137) Yes
TA135 Mesothelioma - pemetrexed disodium (TA135) Yes
TA129 Multiple myeloma - bortezomib (TA129) Yes
TA127 Multiple sclerosis - natalizumab (TA127) Yes
TA124 Lung cancer (non-small-cell) - pemetrexed (TA124) Yes
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121) TA not applicable to this organisation (brain cancers all managed by Leeds Teaching Hospitals NHS Foundation trust)
TA119 Leukaemia (lymphocytic) - fludarabine TA119) Yes
TA118 Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242) Yes
TA116 Breast cancer - gemcitabine (TA116) Yes
TA112 Breast cancer (early) - hormonal treatments (TA112) Yes
TA109 Breast cancer (early) - docetaxel (TA109) Yes
TA108 Breast cancer (early) - paclitaxel (TA108) Yes
TA107 Breast cancer (early) - trastuzumab (TA107) Yes
TA106 Hepatitis c - Peginterferon alfa and ribavirin (TA106) Yes
TA105 Colorectal cancer - laparoscopic surgery (review) (TA105) Yes
TA101 Prostate cancer (hormone-refractory) - docetaxel (TA101) Yes
TA100
Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)

Yes
TA99 Renal transplantation - immuno-suppressive regimens for children and adolescents (TA99) Yes
TA91
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topetecan (review) (TA94)
Yes
TA86 Gastrointestinal stromal tumours - imatinib (TA86) Yes (patients with GIST are referred to the specialist team at Leeds Teaching Hospitals NHS Foundation Trust)
TA85 Renal transplantation - immuno-supressive regimens (adults) (TA85) Yes
TA70 Leukaemia (chronic myeloid) - imatinib (patially updated by TA241 and TA251) (TA70) Yes
TA69 Cervical cancer - cervical screening (review) (TA69) TA not applicable to this organisation (cytology samples all processed in Leeds) 
TA65 Non-Hodgkin's lymphoma - rituximab (TA65) Yes
TA61 Colorectal cancer - capecitabine and tegafur uracil (TA61) Yes
TA55 Ovarian cancer - paclitaxel (review) (TA55) Yes
TA34 Breast cancer - trastuzumab (TA34) Yes
TA32 Multiple sclerosis - beta interferon and glatiramer acetate (TA32) Yes
TA29 Leukaemia (lymphocytic) - fludarabine (TA29) Yes
TA25 Pancreatic cancer - gemcitabine (TA25) Yes
TA23 Brain cancer - temoxolomide (TA23) TA not applicable to this trust (all brain cancers are managed by Leeds Teaching Hospitals NHS Foundation Trust)